Evaluation by the Drug Rediscovery Protocol of off-label use of 37 approved cancer drugs on 1,610 patients showed modest activities overall, although subgroups of responders suggest that off-label drug use could be beneficial in tandem with more stringent biomarker selection.
- K. Verkerk
- A. C. Spiekman
- F. Jeurissen